Objective
To summarize the efficacy and safety results of the long-term extension study following UNITI-1, UNITI-2, and IM-UNITI. The following is based on unpublished data.68
Findings
Study Design
▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
Limitations
▬
Summary
▬
Publication Details
Copyright
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. APPENDIX 6, SUMMARY OF THE IM-UNITI EXTENSION STUDY.